FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1519-1521 October 2, 2008 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The Action to Control Cardiovascular Risk in Diabetes Study Group Related Article by The ADVANCE Collaborative Group PubMed Citation

To the Editor: In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (June 12 issue),¹ the intensive-therapy group differed from the standard-therapy group not only in the glycated hemoglobin level achieved but also in the number of drug classes prescribed to achieve it. It is plausible that in the subgroup of patients with a baseline glycated hemoglobin level of 8% or less who had a benefit with intensive treatment, the target glycated hemoglobin level was achieved with fewer drug classes than in the subgroup of patients with a higher baseline glycated hemoglobin level. Thus, one wonders whether the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.